Type 2 diabetes trials in Japan

29 of 31 trials · From ClinicalTrials.gov, checked 15 November 2026. Ask the study team whether a trial fits you.

• Phase 3Taking people
  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  Where

  Aichi, Kariya, Aichi, Kasugai, Aichi, Nagoya, Chiba, Chiba, Chiba, Ichikawa, Chiba, Matsudo, Chiba, Narashino, Ehime, Matsuyama, Fukuoka, Chikushino, Fukuoka, Fukuoka, Gumma, Maebashi, Gumma, Takasaki, Hiroshima, Hiroshima, Hiroshima, Kure, Hokkaido, Asahikawa, Hokkaido, Sapporo, Hyogo, Nishinomiya, Ibaraki, Higashiibaraki-gun, Ibaraki, Mito, Ibaraki, Naka, Ibaraki, Tsukuba, Ishikawa, Kanazawa, Iwate, Morioka, Kagawa, Kanonji, Kagawa, Takamatsu, Kagoshima, Kagoshima, Kanagawa, Miura-gun, Kanagawa, Sagamihara, Kanagawa, Yokohama, Kochi, Kochi, Kumamoto, Kumamoto, Kumamoto, Kyoto, Kyoto, Miyagi, Sendai, Miyazaki, Miyakonojo, Nagano, Matsumoto, Nagasaki, Nagasaki, Okayama, Okayama, Osaka, Daito, Osaka, Matsubara, Osaka, Moriguchi, Osaka, Osaka, Osaka, Suita, Saitama, Ageo, Saitama, Koshigaya, Saitama, Saitama, Saitama, Tokorozawa, Shizuoka, Fujieda, Shizuoka, Sunto-gun, Tochigi, Shimotsuga-gun, Tochigi, Shimotsuke, Tokushima, Tokushima, Tokyo, Hachioji, Tokyo, Itabashi-ku, Tokyo, Minato-ku, Tokyo, Ota-ku, Toyama, Toyama, Toyoake-shi

  Age

  18 years and over

  People

  11,800 worldwide

  Run by

  Boehringer Ingelheim

  See details and how to joinNCT07064473 · EU 2025-521188-11-00
• Phase 3Not yet taking people in Japan
  A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise

  Where

  Chiba-shi, Chiba, Suita-shi, Tokyo

  Age

  18 years and over

  People

  200 worldwide

  Run by

  Novo Nordisk A/S

  See details and how to joinNCT07931495 · EU 2026-525470-18-00
• Phase 3Not yet taking people in Japan
  A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Treated With Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or Both

  Where

  Aichi, Arakawa-ku, Tokyo, Chiba-shi, Chiba, Chikushino-shi, Fukuoka, Gifu, Ibaraki, Kamakura-shi, Kanagawa, Koriyama-shi, Fukushima, Minato-ku, Tokyo, Mito-shi, Ibaraki, Oita-shi, Oita,, Sendai, Miyagi, Tamana-shi, Kumamoto, Tokyo, Tsu-shi, Mie, Wakayama

  Age

  18 years and over

  People

  450 worldwide

  Run by

  Novo Nordisk A/S

  See details and how to joinNCT07931547 · EU 2026-525471-13-00
• Phase 3Not yet taking people in Japan
  A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both

  Where

  Aichi, Chiba-shi, Chiba, Hokkaido, Koriyama-shi, Fukushima, Shinjuku-ku, Tokyo, Suita-shi, Tokyo

  Age

  18 years and over

  People

  1,060 worldwide

  Run by

  Novo Nordisk A/S

  See details and how to joinNCT07931599 · EU 2026-525474-20-00
• Phase 3Taking people
  A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

  Where

  Aichi, Fukuoka, Hokkaido, Osaka, Tokyo

  Age

  18 years and over

  People

  2,000 worldwide

  Run by

  Hoffmann-La Roche

  See details and how to joinNCT07351045 · EU 2025-523104-71-00
• Phase 3Taking people
  A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

  Where

  Aichi, Fukuoka, Hokkaido, Osaka, Tokyo

  Age

  18 years and over

  People

  1,600 worldwide

  Run by

  Hoffmann-La Roche

  See details and how to joinNCT07351058 · EU 2025-523106-32-00
• Phase 3Taking people
  A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus

  Where

  Chūōku, Ichinomiya-shi, Izunokuni-shi, Kamakura-shi, Kawagoe-shi, Kitakyushu-shi, Kyoto, Mito, Nishinomiya-shi, Ōmihachiman, Yokohama

  Age

  18 years and over

  People

  500 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT07776509 · EU 2025-523295-23-00
• Phase 3Taking people
  A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

  Where

  Chuo-ku, Shinjuku-ku, Suita

  Age

  18 years and over

  People

  954 worldwide

  Run by

  Pfizer

  See details and how to joinNCT07595549 · EU 2026-525318-75-00
• Phase 3Taking people
  A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

  Where

  Chiyoda-ku, Fukuoka, Iruma, Moriyama, Niigata, Osaka, Saitama, Sendai, Shizuoka, Tokyo, Urayasu

  Age

  10 years to 17 years

  People

  170 worldwide

  Run by

  Eli Lilly and Company

  See details and how to joinNCT07668336 · EU 2025-524811-35-00
• Phase 3Taking people
  A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

  Where

  Chigasaki, Chūōku, Kamakura, Kasuya-gun, Kawaguchi, Kita-ku, Mihama-ku,Chiba City, Naha, Oyama, Setagaya-ku, Sōka, Tsuchiura, Ushiku, Yokohama

  Age

  18 years and over

  People

  1,035 worldwide

  Run by

  Eli Lilly and Company

  See details and how to joinNCT07282600 · EU 2025-523658-15-00
• Phase 3Taking people
  A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

  Where

  Chūōku, Izumisano, Kawasaki, Kisarazu, Kure, Kyoto, Matsuyama, Osaka, Sapporo, Shimonoseki, Wakayama

  Age

  18 years and over

  People

  900 worldwide

  Run by

  Eli Lilly and Company

  See details and how to joinNCT07392190 · EU 2025-523659-73-00
• Phase 3Not yet taking people in Japan
  A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes

  Where

  Chūōku, Narashino, Sōka, Tsuchiura

  Age

  18 years and over

  People

  1,000 worldwide

  Run by

  Eli Lilly and Company

  See details and how to joinNCT07881458 · EU 2026-527230-31-00
• Phase 2Taking people
  A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

  Where

  Hachiōji, Kamakura-shi, Naka, Narita

  Age

  18 years and over

  People

  120 worldwide

  Run by

  Eli Lilly and Company

  See details and how to joinNCT07783802
• Phase 3Not yet taking people in Japan
  A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes

  Where

  Chiyoda City, Chūōku, Kawasaki, Kin-cho, Kunigami-gun, Nerima-ku, Shinjuku, Shinjuku-ku, Urasoe

  Age

  18 years and over

  People

  2,115 worldwide

  Run by

  Eli Lilly and Company

  See details and how to joinNCT07881432 · EU 2026-526047-34-00
• Phase 3Not yet taking people in Japan
  A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk

  Where

  Hamadayama, Suginami-ku, Himeji, Kisarazu, Kōriyama, Kumamoto, Kurume, Osaka, Shinjyuku, Uji

  Age

  45 years to 64 years

  People

  3,000 worldwide

  Run by

  Eli Lilly and Company

  See details and how to joinNCT07900633 · EU 2026-525919-14-00
• Phase 3Taking people
  A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus

  Where

  Chūōku, Fukuoka, Hachioji-shi, Ichikawa-shi, Kamakura-shi, Kishiwada-shi, Kitakyushu, Meguro-ku, Mito, Sapporo, Shinjuku-ku, Soka-shi, Tama-shi, Yamato-shi, Yokohama

  Age

  18 years and over

  People

  2,000 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT07662109 · EU 2025-523941-81-00
• Phase 3Taking people
  A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

  Where

  Chūōku, Fukuoka, Hachioji-shi, Osaka, Shibuya-ku, Takatsuki-shi

  Age

  18 years and over

  People

  2,500 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT07784725 · EU 2025-523379-41-00
• Phase 3Taking people
  A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

  Where

  Aira, Chūōku, Fukuoka, Hachioji-shi, Izunokuni-shi, Kumamoto, Nagoya, Nerima-ku, Osaka, Saga, Sapporo, Shinjuku-ku, Suita-shi, Tanabe-shi

  Age

  18 years and over

  People

  1,500 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT07784270
• Phase 3Taking people
  A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus

  Where

  Asahikawa-shi, Chūōku, Kamakura-shi, Koga-shi, Kumamoto, Mitaka-shi, Mito, Miyazaki, Nagoya, Naka, Nishinomiya-shi, Osaka, Sapporo, Takamatsu

  Age

  18 years and over

  People

  1,200 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT07662213 · EU 2025-523933-24-00
• Phase 3Taking people
  A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

  Where

  Amagasaki-shi, Chūōku, Kasugai-shi, Koga-shi, Maebashi, Minatoku, Naka, Shinjuku-ku, Shizuoka, Suita-shi, Toshima-ku, Yamato-shi, Yokohama

  Age

  18 years and over

  People

  4,500 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT07667803
• Phase 3Taking people
  Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

  Where

  Aki-gun, Kashiwara-shi, Kitakyusyu-shi, Kumamoto, Matsuyama, Meguro-ku, Mitaka-shi, Mito, Naka, Shizuoka, Tsuchiura-shi

  Age

  18 years to 99 years

  People

  950 worldwide

  Run by

  Amgen

  See details and how to joinNCT07684144 · EU 2025-524788-19-00
• Phase 3Taking people
  A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

  Where

  Adachi-ku, Chūōku, Fukuoka, Minato, Mitaka, Suita-shi, Tokyo

  Age

  18 years and over

  People

  1,980 worldwide

  Run by

  Eli Lilly and Company

  See details and how to joinNCT07321886 · EU 2025-523657-34-00
• Phase 2Active, not recruiting
  A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

  Where

  Chiba-shi, Chiba, Ibaraki, Soka-shi, Saitama, Tokyo

  Age

  18 years to 75 years

  People

  270 worldwide

  Run by

  Novo Nordisk A/S

  See details and how to joinNCT07415954 · EU 2025-523260-20-00
• Phase 3Taking people
  A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin

  Where

  Chigasaki-shi, Chikushino-shi, Gifu, Kagoshima, Kitakyushu, Kumamoto, Kyoto, Maebashi, Nagoya, Osaka, Sapporo, Suita-shi, Tachikawa-shi, Toyota-Shi

  Age

  18 years and over

  People

  900 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT07662135 · EU 2025-523940-12-00
• Phase 3Not yet taking people in Japan
  A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus

  Where

  Amagasaki-shi, Chiba, Chitose-shi, Chūōku, Koga-shi, Minatoku, Okayama, Oyama-shi, Shinjuku-ku, Zentsuji-shi

  Age

  18 years and over

  People

  800 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT07662044 · EU 2025-523936-37-00